Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARIANE neoadjuvant intradermal ipilimumab and nivolumab in high-risk stage II melanoma
NL-OMON59982Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ipilimumab and nivolumab in melanoma, sponsored by Netherlands Cancer Institute. Started Mar 2024; status: recruiting.
02
Drugs
ipilimumabnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON59982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59982.